Syndax Pharmaceuticals (NASDAQ:SNDX) Upgraded by StockNews.com to Hold Rating

Syndax Pharmaceuticals (NASDAQ:SNDX) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Thursday.

Several other analysts have also recently issued reports on SNDX. HC Wainwright upped their price objective on Syndax Pharmaceuticals from $45.00 to $47.00 and gave the stock a “buy” rating in a report on Wednesday. Stifel Nicolaus upped their price objective on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Bank of America upped their price objective on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, August 15th. The Goldman Sachs Group upped their price objective on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Citigroup increased their price target on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a “buy” rating in a report on Friday, August 16th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Syndax Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $35.82.

Syndax Pharmaceuticals Stock Up 0.8 %

SNDX stock traded up $0.17 during midday trading on Thursday, hitting $21.52. The company’s stock had a trading volume of 1,116,210 shares, compared to its average volume of 1,065,171. Syndax Pharmaceuticals has a 12 month low of $13.14 and a 12 month high of $25.34. The firm has a market capitalization of $1.83 billion, a price-to-earnings ratio of -6.37 and a beta of 0.92. The company has a 50 day moving average of $19.09 and a two-hundred day moving average of $20.33.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.13) by $0.15. The business had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same quarter in the previous year, the company earned ($0.73) earnings per share. On average, analysts anticipate that Syndax Pharmaceuticals will post -3.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. bought a new position in shares of Syndax Pharmaceuticals during the 2nd quarter worth $27,000. Values First Advisors Inc. bought a new position in shares of Syndax Pharmaceuticals during the 3rd quarter worth $30,000. nVerses Capital LLC bought a new position in shares of Syndax Pharmaceuticals during the 2nd quarter worth $33,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Syndax Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after purchasing an additional 541 shares in the last quarter. Finally, Quarry LP boosted its position in Syndax Pharmaceuticals by 75.0% during the second quarter. Quarry LP now owns 6,125 shares of the company’s stock valued at $126,000 after purchasing an additional 2,625 shares in the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).